文献速递神经MR

减少剂量钆布醇与标准剂量钆特酸用于中枢神经系统增强MRI的临床疗效:国际多中心前瞻性交叉试验(LEADER-75)

Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75).
PubMed 文献 · AJR Am J Roentgenol · 2021-06-16

国际前瞻性多中心开放标签交叉试验纳入141例已知或疑似中枢神经系统病变成人,先以标准剂量钆特酸(0.1 mmol/kg)行脑增强MRI,发现强化病灶者15天内再以减量钆布醇(0.075 mmol/kg)复查。三位放射科医师独立评分显示,减量钆布醇在病灶强化、边界勾勒及内部形态三项主要疗效指标上非劣于标准剂量钆特酸,事后分析支持等效。

要点

  • 减量钆布醇(0.075 mmol/kg)在病灶强化、边界及内部形态评分上非劣于标准剂量钆特酸(0.1 mmol/kg)。
  • 事后分析显示三项主要疗效指标平均评分差异小于1%,在±5%界值内支持等效。
  • 减量钆布醇与标准剂量钆特酸对恶性肿瘤的敏感度(58.7%)、特异度(91.8%)和准确率(70.2%)相同。

核心结论

  • 25%减量钆布醇对脑增强MRI的疗效非劣于标准剂量钆特酸。

研究设计与样本

  • 国际前瞻性多中心开放标签交叉试验(LEADER-75),纳入141例已知或疑似中枢神经系统病变的成人(78男,63女,平均年龄58.5±13.5岁);先以标准剂量钆特酸(0.1 mmol/kg)行脑增强MRI,发现强化病灶者15天内再以减量钆布醇(0.075 mmol/kg)复查;三位放射科医师独立评分。

诊断标准与关键数值

  • 非劣效界值定义为减量钆布醇较平扫的评分改善至少达到标准剂量钆特酸较平扫评分改善的80%;采用20%非劣效界值时三项主要疗效指标均达非劣效(p≤.025);事后分析采用±5%界值支持等效(p≤.025)。

临床应用与阅片要点

  • 作者认为脑MRI可考虑使用减量钆布醇,尤其适用于需多次增强检查的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Gadobutrol and gadoterate are widely used macrocyclic gadolinium-based contrast agents. Given gadobutrol's higher T1 relaxivity, a reduced gadobutrol dose should achieve essentially equivalent diagnostic efficacy as a standard dose of gadoterate. OBJECTIVE. The purpose of our study was to show efficacy of a 25% reduced dose of gadobutrol is noninferior to 100% standard dose of gadoterate for contrast-enhanced MRI of the CNS. METHODS. In this international prospective multicenter open-label crossover trial (LEADER-75 [Lower Administered Dose With Higher Relaxivity: Gadovist vs Dotarem]), adult patients with known or suspected CNS pathology underwent contrast-enhanced brain MRI with standard-dose gadoterate (0.1 mmol/kg); if an enhancing lesion was identified, a second MRI with reduced-dose gadobutrol (0.075 mmol/kg) was performed within 15 days of the first MRI. Three radiologists independently reviewed images to score three primary efficacy measures: subjective lesion enhancement, lesion border delineation, lesion internal morphology. A noninferiority analysis used readers' mean scores of the primary efficacy measures. Noninferiority of reduced-dose gadobutrol to standard-dose gadoterate for primary efficacy measures was defined as the difference in score between reduced-dose gadobutrol images and unenhanced images achieving at least 80% of the difference in score between standard-dose gadoterate images and unenhanced images. A post hoc analysis was performed to directly compare contrast-enhanced images for equivalence. Secondary efficacy variables included the number of lesions detected, reader confidence, diagnostic performance for malignancy, and reader preference in side-by-side comparison. RESULTS. The efficacy analysis included 141 patients (78 men, 63 women; mean age, 58.5 ± 13.5 [SD] years). Improvement of reduced-dose gadobutrol over unenhanced images was noninferior to improvement of standard-dose gadoterate over unenhanced images using a 20% noninferiority margin for all three primary efficacy measures using mean readings (p ≤ .025). In the post hoc analysis, the mean reading for the three primary efficacy measures differed by less than 1% between reduced-dose gadobutrol and standard-dose gadoterate, supporting equivalence of all measures using a narrow ± 5% margin (p ≤ .025). The total number of lesions detected by mean reading was 301 for reduced-dose gadobutrol versus 291 for standard-dose gadoterate. Mean reader confidence was 3.3 ± 0.6 for reduced-dose gadobutrol versus 3.3 ± 0.6 for standard-dose gadoterate. Sensitivity (58.7%), specificity (91.8%), and accuracy (70.2%) for malignancy from majority reading were identical for reduced-dose gadobutrol and standard-dose gadoterate. Reader preference was not different (95% CI, -0.10 to 0.11). CONCLUSION. A 25% reduced dose of gadobutrol is noninferior to standard-dose gadoterate for contrast-enhanced brain MRI. CLINICAL IMPACT. Use of reduced-dose gadobutrol should be considered for brain MRI, particularly in patients undergoing multiple contrast-enhanced examinations. TRIAL REGISTRATION. ClinicalTrials.gov NCT03602339; EU Clinical Trials Register EudraCT 2018-00690-78.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Liu BP, Rosenberg M, Saverio P, et al. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75). AJR Am J Roentgenol. 2021. PMID: 34133205. doi:10.2214/AJR.21.25924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。